IWM
CRSP icon

IHT Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

IHT Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,464
Closed -$295K – 1152
2024
Q2 		$295K Sell
5,464
-1,344
-20% -$77.7K 0.01% 806
2024
Q1 		$464K Sell
6,808
-110
-2% -$7.88K 0.02% 663
2023
Q4 		$433K Sell
6,918
-652
-9% -$36K 0.02% 650
2023
Q3 		$344K Sell
7,570
-400
-5% -$20.7K 0.02% 675
2023
Q2 		$447K Sell
7,970
-211
-3% -$12K 0.02% 581
2023
Q1 		$370K Sell
8,181
-1,919
-19% -$93.2K 0.02% 616
2022
Q4 		$411K Buy
10,100
+55
+0.5% +$2.92K 0.03% 548
2022
Q3 		$656K Buy
10,045
+2,668
+36% +$193K 0.05% 380
2022
Q2 		$448K Sell
7,377
-8
-0.1% -$470 0.04% 409
2022
Q1 		$464K Hold
7,385
– – 0.04% 431
2021
Q4 		$560K Buy
7,385
+835
+13% +$72.9K 0.04% 402
2021
Q3 		$733K Sell
6,550
-2,750
-30% -$345K 0.06% 318
2021
Q2 		$1.51M Buy
9,300
+700
+8% +$85.1K 0.1% 224
2021
Q1 		$1.05M Sell
8,600
-816
-9% -$123K 0.08% 259
2020
Q4 		$1.44M Buy
9,416
+1,609
+21% +$190K 0.12% 176
2020
Q3 		$653K Buy
7,807
+3,428
+78% +$304K 0.07% 275
2020
Q2 		$322K Buy
+4,379
New +$256K 0.04% 393
2019
Q3 		– Sell
-5,383
Closed -$254K – 614
2019
Q2 		$254K Buy
+5,383
New +$215K 0.04% 433
2018
Q4 		– Sell
-5,051
Closed -$224K – 481
2018
Q3 		$224K Hold
5,051
– – 0.05% 386
2018
Q2 		$297K Sell
5,051
-500
-9% -$28.5K 0.08% 305
2018
Q1 		$240K Buy
5,551
+50
+0.9% +$2.06K 0.06% 320
2017
Q4 		$143K Hold
5,501
– – 0.04% 411
2017
Q3 		$108K Sell
5,501
-126
-2% -$2.29K 0.05% 343
2017
Q2 		$20 Buy
5,627
+80
+1% +$1.32K 0.01% 778
2017
Q1 		$110K Buy
+5,547
New +$109K 0.07% 264

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

IHT Wealth Management's CRSP Position: Q3 2024 in Review

IHT Wealth Management sold out of CRISPR Therapeutics (CRSP) in Q3 2024, closing a stake of 5,464 shares — an estimated $295K sold.

IHT Wealth Management first reported a position in CRSP in Q1 2017 and held it in 25 quarters. The position peaked at $1.51M in Q2 2021. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

  • IHT Wealth Management reported no remaining CRISPR Therapeutics position as of Q3 2024 after selling out during the quarter.
  • IHT Wealth Management sold 5,464 CRISPR Therapeutics shares in Q3 2024, an estimated $295K.
  • IHT Wealth Management first reported a position in CRISPR Therapeutics in Q1 2017 and held it in 25 quarters.
  • IHT Wealth Management's CRISPR Therapeutics position peaked at $1.51M in Q2 2021.
  • 416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on IHT Wealth Management's 13F filing for Q3 2024, filed 14 Nov 2024.